Detalhe da pesquisa
1.
A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma.
Cell
; 187(1): 166-183.e25, 2024 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38181739
2.
Relatlimab and nivolumab in the treatment of melanoma.
Cell
; 185(26): 4866-4869, 2022 12 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36563660
3.
Topical therapy for regression and melanoma prevention of congenital giant nevi.
Cell
; 185(12): 2071-2085.e12, 2022 06 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35561684
4.
LAG-3 as the third checkpoint inhibitor.
Nat Immunol
; 24(9): 1415-1422, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37488429
5.
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.
Cell
; 183(2): 347-362.e24, 2020 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33064988
6.
A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance.
Nat Immunol
; 23(5): 660-670, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35241833
7.
Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade.
Cell
; 178(4): 933-948.e14, 2019 08 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31398344
8.
Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy.
Nat Immunol
; 22(8): 1052-1063, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34168370
9.
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.
Cell
; 175(4): 984-997.e24, 2018 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30388455
10.
An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.
Cell
; 173(6): 1413-1425.e14, 2018 05 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-29754815
11.
Toward Minimal Residual Disease-Directed Therapy in Melanoma.
Cell
; 174(4): 843-855.e19, 2018 08 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30017245
12.
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.
Cell
; 167(6): 1540-1554.e12, 2016 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27912061
13.
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.
Cell
; 165(1): 35-44, 2016 Mar 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-26997480
14.
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.
Cell
; 167(2): 397-404.e9, 2016 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27667683
15.
Antigen and checkpoint receptor engagement recalibrates T cell receptor signal strength.
Immunity
; 54(11): 2481-2496.e6, 2021 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34534438
16.
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.
Cell
; 162(6): 1271-85, 2015 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26359985
18.
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity.
Cell
; 162(6): 1257-70, 2015 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26343581
19.
Broad-spectrum therapeutic suppression of metastatic melanoma through nuclear hormone receptor activation.
Cell
; 156(5): 986-1001, 2014 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-24581497
20.
Non-cell-autonomous cancer progression from chromosomal instability.
Nature
; 620(7976): 1080-1088, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37612508